A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Localized Non-germinomatous Central Nervous System Germ Cell Tumor
  • Age: Between 3 - 30 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patients must be newly diagnosed with localized primary CNS NGGCT of the suprasellar and/or pineal region by pathology and/or serum or CSF elevation of AFP above institutional normal or > 10 ng/mL or hCGß > 100 mIU/mL.
    2. Patients with any of the following pathological elements are eligible: endodermal sinus (yolk sac), embryonal carcinoma, choriocarcinoma, malignant/immature teratoma and mixed GCT.
    3. Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled.

You may not be eligible for this study if the following are true:

    1. Patients with tumors located outside the ventricles (i.e., basal ganglia, thalamus); mature teratoma and non-elevated markers upon tumor sampling at diagnosis.
    2. Patients who have received any prior tumor-directed therapy for their diagnosis of NGGCT other than surgical intervention and corticosteroids.
    3. Patients with metastatic disease (i.e., MRI evaluation, lumbar CSF cytology or intraoperative evidence of dissemination).
    4. Patients in status epilepticus, coma or assisted ventilation prior to study enrollment.
    5. Pregnancy and Breastfeeding



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.